| Literature DB >> 30123509 |
Kent Doi1, Osamu Nishida2, Takashi Shigematsu3, Tomohito Sadahiro4, Noritomo Itami5, Kunitoshi Iseki6, Yukio Yuzawa7, Hirokazu Okada8, Daisuke Koya9, Hideyasu Kiyomoto10, Yugo Shibagaki11, Kenichi Matsuda12, Akihiko Kato13, Terumasa Hayashi14, Tomonari Ogawa15, Tatsuo Tsukamoto16, Eisei Noiri17, Shigeo Negi3, Koichi Kamei18, Hirotsugu Kitayama19, Naoki Kashihara20, Toshiki Moriyama21, Yoshio Terada22.
Abstract
Acute kidney injury (AKI) is a syndrome which has a broad range of etiologic factors depending on different clinical settings. Because AKI has significant impacts on prognosis in any clinical settings, early detection and intervention are necessary to improve the outcomes of AKI patients. This clinical guideline for AKI was developed by a multidisciplinary approach with nephrology, intensive care medicine, blood purification, and pediatrics. Of note, clinical practice for AKI management which was widely performed in Japan was also evaluated with comprehensive literature search.Entities:
Keywords: Acute kidney injury; Atrial natriuretic peptide; Biomarker; Blood purification; Long-term follow-up; Nafamostat mesilate
Year: 2018 PMID: 30123509 PMCID: PMC6088399 DOI: 10.1186/s40560-018-0308-6
Source DB: PubMed Journal: J Intensive Care ISSN: 2052-0492